Ferdja Ferdja.com delivers the latest news and relevant information across various domains including politics, economics, technology, culture, and more. Stay informed with our detailed articles and in-depth analyses.
By Jacob Gronholt-Pedersen
COPENHAGEN (Reuters) – Novo Nordisk has actually released its Wegovy weight-loss medication in Australia, the drugmaker stated on Thursday, making the extremely preferred medicine offered in 12 nations.
Novo, which has actually had a hard time to fulfill runaway need for its first-to-market medicine, is looking for to obtain a grip in brand-new nations in advance of competitors such as Eli Lilly.
It is a market that experts approximate can be worth approximately $100 billion by the end of the years.
The Danish business stated Wegovy was offered in Australia in regular shot of 2.4 milligram dosages of semaglutide, the energetic component in the medicine.
2 out of 3 grownups in Australia were obese or overweight in 2022, according to the Australian Institute of Health And Wellness and Well-being.
The medicine will certainly not be subsidised under the Drug Perks Plan, and people will certainly require a prescription from their medical professional, Novo Nordisk stated.
The business released the medicine in Spain and Canada in May. It is additionally offered in the USA, Denmark, Norway, Switzerland, United Arab Emirates, Japan, Britain, Germany and Iceland.
( Coverage by Jacob Gronholt-Pedersen; modifying by Louise Breusch Rasmussen and Jason Neely)
